Pegfilgrastim Biosimilars Market Growth Analysis With Investment Opportunities For 2024-2033

The Business Research Company's Pegfilgrastim Biosimilars Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 29, 2024 /EINPresswire.com/ -- The pegfilgrastim biosimilars market has experienced robust growth in recent years, expanding from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.

Strong Future Growth Anticipated
The pegfilgrastim biosimilars market is projected to continue its strong growth, reaching $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives.

Explore Comprehensive Insights Into The Global Pegfilgrastim Biosimilars Market With A Detailed Sample Report:
https://www.thebusinessresearchcompany.com/sample_request?id=4015&type=smp

Growth Driver Of The Pegfilgrastim Biosimilars Market
The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Pegfilgrastim biosimilars are used to reduce the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production.

Order Your Report Now For Swift Delivery:
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Major Players And Market Trends
Key players in the pegfilgrastim biosimilars market include Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd., Mundipharma GmbH, Dr. Reddy’s Laboratories, Pfizer Inc.
Major companies operating in the pegfilgrastim biosimilars market are launching high-quality pegfilgrastim biosimilars such as the Stimufend to provide better alternatives. Stimufend is a therapeutic drug designed to assist cancer patients in addressing neutropenia.

Segments:
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Geographical Insights: North America Leading The Market
North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Pegfilgrastim Biosimilars Market Definition
Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

Pegfilgrastim Biosimilars Global Market Report 2024 from The Business Research Company covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Pegfilgrastim Biosimilars Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on pegfilgrastim biosimilars market size, pegfilgrastim biosimilars market drivers and trends, pegfilgrastim biosimilars market major players, pegfilgrastim biosimilars competitors' revenues, pegfilgrastim biosimilars market positioning, and pegfilgrastim biosimilars market growth across geographies. The pegfilgrastim biosimilars market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Trastuzumab Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn